A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
NCT00469352
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Macular Degeneration
Interventions
DRUG:
Ranibizumab
Sponsor
Oregon Health and Science University